PARIS & BOSTON–(BUSINESS WIRE)–Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reports its consolidated results for the first half of 2026, as approved by the Board of Directors on September 28, 2026. The half-year financial report will be available on the Company’s website. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “T